Clinical Pharmacist and Master’s student in Clinical Pharmacy with research interests in pharmacovigilance, behavioral interventions in mental health, and AI applications in clinical decision support. Experience includes digital health research with Bloomsbury Health (London) and pharmacovigilance practice in patient support programs. Published work covers drug awareness among healthcare providers, postpartum depression management, and patient safety reporting. 
Clinical Pharmacist and Master’s student in Clinical Pharmacy with research interests in pharmacovigilance, behavioral interventions in mental health, and AI applications in clinical decision support. Experience includes digital health research with Bloomsbury Health (London) and pharmacovigilance practice in patient support programs. Published work covers drug awareness among healthcare providers, postpartum depression management, and patient safety reporting. What was reviewed
This comprehensive review article, “Arsenic and Environmental Health: State of the Science and Future Research Opportunities,” examined the current state of research on environmental arsenic exposure, its health effects, and mitigation strategies. The focus was on identifying critical gaps in knowledge, emerging research priorities, and strategies for better assessment, prevention, and management of arsenic-related health risks. Drawing from a large body of literature and insights from a multidisciplinary workshop convened by the National Institute of Environmental Health Sciences (NIEHS) Superfund Research Program, the review synthesizes findings on arsenic speciation, exposure sources (including water, diet, soil, dust, and air), bioavailability, aggregate exposure assessment, biomarkers, co-exposures, the role of the microbiome, and population susceptibility. The review also explores technological and behavioral strategies for exposure reduction and discusses future directions for integrating ‘omics’ data with epidemiology to inform risk assessment and regulatory policy.
Who was reviewed
The review synthesized research findings from a broad array of studies involving populations worldwide exposed to arsenic through diverse environmental media. These included epidemiological cohorts in Bangladesh, the United States, Chile, and other regions with high arsenic levels in water or food. The review also covered laboratory-based investigations using animal models and in vitro systems to elucidate arsenic metabolism, bioavailability, and toxicity. Additionally, it incorporated studies on susceptible populations, such as children, pregnant women, and individuals with genetic or nutritional differences affecting arsenic metabolism. The reviewed literature spanned both human and animal data, with an emphasis on populations living near contaminated sites, those reliant on rice-based diets, and individuals with varying genetic susceptibilities to arsenic toxicity.
Most important findings
| Critical Points | Details |
|---|---|
| Arsenic exists in multiple chemical forms with differing toxicity and bioavailability | Inorganic arsenic species (As(III), As(V)) are generally more toxic than organic forms like arsenobetaine. However, some organoarsenicals (e.g., arsenosugars, arsenolipids, thiolated arsenic) remain poorly characterized in terms of toxicity and bioavailability, presenting challenges for accurate risk assessment and management. |
| Major exposure sources extend beyond drinking water | While contaminated drinking water is a well-known risk, food (especially rice and seafood), soil, dust, and air can contribute significantly to aggregate arsenic exposure, often surpassing water as the primary source in low-water-arsenic settings. |
| Assessment of aggregate exposure is complex and data-limited | The totality of arsenic exposure reflects contributions from multiple media and species. Accurate assessment requires measuring specific arsenic species and accounting for co-contaminants and individual variability in metabolism. Current dietary studies often underestimate exposure, and more precise methods (like duplicate diet studies) are costly and rare. |
| Bioavailability varies by medium and arsenic species | Only a portion of arsenic in soil, dust, or food is bioavailable. New in vitro bioaccessibility assays show promise for cost-effective estimation, but require further validation across sample types. |
| Biomarkers and omics approaches are evolving but need refinement | Urinary arsenic (short-term) and toenail arsenic (long-term) are established biomarkers, but their link to internal dose is influenced by renal function, creatinine adjustment, and metabolism (e.g., role of the gut microbiome, nutrition, and genetics). Emerging epigenetic and metabolomic biomarkers may enable early detection and improved risk stratification. |
| Co-exposures with other contaminants (e.g., cadmium, fluoride) may alter toxicity | Interactions between arsenic and other contaminants can be synergistic or antagonistic, affecting health outcomes. Understanding these interactions is crucial for accurate risk assessment and regulation. |
| The gut microbiome influences arsenic metabolism and toxicity | Recent studies reveal that microbiome composition modifies arsenic metabolite profiles and toxicity, suggesting individual variability in susceptibility and challenging one-size-fits-all regulatory limits. |
| Effective mitigation requires combined technological and behavioral interventions | Water filtration, alternative water sourcing, phytostabilization, and nutritional interventions (e.g., folate, selenium) show promise. However, community education, accessibility, and behavioral change are critical for real-world efficacy. |
| Susceptibility is modulated by genetics, life stage, and nutrition | Genetic polymorphisms (e.g., AS3MT), early-life exposure, and nutritional status (folate, selenium, B12) significantly affect arsenic metabolism and health outcomes, highlighting the need for population-specific risk assessment. |
| Data gaps hinder robust risk assessment and regulation | Critical gaps remain in the characterization of non-water exposure pathways, toxicokinetics of less-understood arsenic species, aggregate exposure modeling, and the integration of molecular biomarkers into risk assessment. |
Key implications
For heavy metal certification programs like HMTC, the review highlights that total arsenic measurement is insufficient; detailed speciation analyses are necessary. Certification standards should reflect the complexity of exposure routes (not just water, but also food and environmental media), the variability in bioavailability, and population-specific susceptibilities. Incorporating biomarker and omics data can enhance risk assessment, and mitigation strategies must integrate technological solutions with effective community engagement and education to ensure real-world impact. Co-exposures and nutritional factors should also be considered in certification and regulatory approaches for a more comprehensive protection of public health.
Citation
Carlin DJ, Naujokas MF, Bradham KD, Cowden J, Heacock M, Henry HF, Lee JS, Thomas DJ, Thompson C, Tokar EJ, Waalkes MP, Birnbaum LS, Suk WA. Arsenic and environmental health: state of the science and future research opportunities. Environmental Health Perspectives. 2016;124(7):890-899. http://dx.doi.org/10.1289/ehp.1510209
Arsenic is a naturally occurring metalloid that ranks first on the ATSDR toxic substances list. Inorganic arsenic contaminates water, rice and consumer products, and exposure is linked to cardiovascular disease, cognitive deficits, low birth weight and cancer. HMTC’s stringent certification applies ALARA principles to protect vulnerable populations.
